The U.S. Food and Drug Administration (FDA) has granted priority review to an application seeking approval of pz-cel (prademagene zamikeracel)…
Articles by Marisa Wexler, MS
EB Research Partnership (EBRP), an organization dedicated to funding research into treatments for epidermolysis bullosa (EB), has raised more…
Itch is a common symptom with recessive dystrophic epidermolysis bullosa (RDEB) and available treatments are generally inadequate for managing…
Paradigm Therapeutics has acquired worldwide rights to SD-101, an investigational cream that’s being developed as a whole-body therapy to…
The use of biological anti-inflammatory therapies effectively controlled epidermolysis bullosa acquisita (EBA) in four people with the disease, a…
Abeona Therapeutics has submitted a data briefing package on its cell therapy candidate EB-101 to the U.S. Food…
People with recessive dystrophic epidermolysis bullosa (RDEB) developed fewer new wounds after getting treatment with skin-derived mesenchymal stem cells, a…
Issues with wound healing may play a central role in driving severe forms of epidermolysis bullosa (EB), a new…
A never-before-reported mutation in the KRT14 gene caused epidermolysis bullosa simplex (EBS) in a family in China. The new…
Onconova Therapeutics and Pangea Biomed are teaming up to identify biomarkers that can help predict a response to the experimental…
People with epidermolysis bullosa acquisita (EBA) are at a higher risk of developing other autoimmune disorders, certain types of…
Tofacitinib, a therapy approved for certain inflammatory diseases effectively controlled symptoms of epidermolysis bullosa acquisita (EBA) in a man with…